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Abstract - A convenient and efficient synthesis of new 5-azapurine derivatives was developed. The 
regioisomeric 5-amino-6,7-dihydro- and 7-amino-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines 
were prepared in 3-4 steps from benzhydrazide via complementary and regiospecific routes as a part of 
our lead finding program. The molecular structures and tautomeric preferences of the compounds 
obtained were investigated using NMR spectral data and X-ray crystallography.  
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1. Introduction 
Dihydrofolate reductase (DHFR) plays an essential role in cellular biochemistry and has been a well-
recognized drug target for half a century. Antifolate drugs have been developed as anticancer, 
antibacterial, antifungal and antiparasitic agents.2 4,6-Diamino-1,2-dihydro-1,3,5-triazines (e.g 
antimalarial drug cycloguanil and WR 99210) are known to be potent inhibitors of DHFR.2a,b Recently, 
dihydro-1,3,5-triazino[1,2-a]benzimidazoles (1) (Fig. 1) have also been found to possess antifolate 
activity.3 Reports on other examples of fused dihydro-1,3,5-triazine with DHFR inhibitory activity are 
limited.  
As a continuation to our investigation on fused 1,3,5-triazines as potential inhibitors of DHFR,3a,4 we 
became interested in the aza-analogues of the purine system that carries a bridge nitrogen, particularly 
the 1,2,4-triazolo[1,5-a][1,3,5]triazines (5-azapurines).1 The 1,2,4-triazolo[1,5-a][1,3,5]triazine 
derivatives have been shown to possess a wide range of biological activities.5 However, antifolate 
activity of the compounds with this heterocyclic scaffold has not been investigated.  
There are some common structural features which are unique to the triazine antifolates: 1) one of the 
carbon atoms of triazine ring should be in sp3 hybridization (gem-dimethyl substitution is usually 
prefered); 2) the other two carbon atoms ought to be connected with nitrogen atoms of amino group or 
fused ring; 3) lypophilic aromatic moiety is required at the distal part of molecule. In this report we 
describe new practical synthesis of derivatives of 5-azapurine system, viz. hitherto unknown 
regioisomeric 5-amino-6,7-dihydro- and 7-amino-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines (2 
and 3). These compounds contain in the structure pharmacophoric fragments (Fig. 1) of the triazine 
DHFR inhibitors and potentially may interact with this enzyme.  
We designed a 3-4 step synthesis of dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines 2 and 3 from 
benzhydrazide (4) with the subsequent formation of the 1,2,4-triazole and the 1,3,5-triazine rings using 
simple procedures, inexpensive and readily available reagents that make this synthetic approach very 
practical. The final step that leads to the annulation of the 1,3,5-triazine nucleus, can be successfully 
achieved via cyclization of the suitably substituted 1,2,4-triazoles, i.e. 5-guanidino-3-phenyl-1,2,4-
triazole (5) and 5-amino-1-guanyl-3-phenyl-1,2,4-triazole (6) with aldehydes or ketones 7 to generate 
the libraries for biological screening (Scheme 1).  
 
2. Results and discussion 
The reactions of benzhydrazide (4) with cyanoguanidine in the presence of hydrochloric acid gave N-
benzamidobiguanide (8) (Scheme 2). The treatment of N-benzamidobiguanide (8) with aqueous alkali 
resulted in 1,2,4-triazole ring closure and provided 5-guanidino-1,2,4-triazole 5.  
The heating of 5-guanidino-1,2,4-triazole 5 with carbonyl compounds 7 in ethanol in the presence of 
piperidine gave 5-amino-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines 2 (Scheme 3, Table 1). This 
heterocyclization was found to proceed smoothly with a variety of aldehydes and ketones. The reaction 
was regioselective and afforded only the products of the ring closure to nitrogen atom N-1 of the 
triazole 5; the products of the ring closure to nitrogen atom N-4 (compounds 10) as well as possible 
intermediates 9 were not isolated. The signal of sp3-hybridized carbon atom in 13C NMR spectra at 62-
80 ppm indicated that the triazine ring closure had occurred. The triazolotriazine structures 2 and 10 
were differentiated using 2D NOESY experiments (no cross-peaks were found between R1 or R2 and 
phenyl group) and X-ray crystallography of compound 2h (Fig. 2).6 
The synthesis of the regioisomeric 7-amino-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines (3) was 
also initiated from benzhydrazide (4). The reactions of 4 with S-methyl isothiourea gave N’-
benzamidoguanidine (11) (Scheme 4). The two signals of NH2 groups in 1H NMR spectra of the 
compound 11 indicated that tautomeric form 11, rather than form 11’, was preferred in DMSO solution 
(ΔG‡316 = 67.6 kJ). N-Benzamidoguanidine (11) was found to be stable: it could be recrystallized from 
water or aqueous ethanol and no changes were observed after drying at 140 ºC under vacuum for 24 h.  
In general, N-benzamidoguanidine (11) could be cyclised to aminotriazoles with elimination of water 
molecule. The reported methods7 required heating of 11 to above its mp (220 ºC) or refluxing with 
sodium ethoxide. We found that the ring closure could be achieved easier and with higher yield. When 
N-benzamidoguanidine (11) was heated in water, the triazole 12 was obtained in almost quantitative 
yield (Scheme 4). The reaction was found to be clean and afforded 12 with excellent purity. 1H NMR 
spectroscopy studies of the 1,2,4-triazoles 12 in DMSO solution concluded that 5-amino-3-phenyl-
1,2,4-triazole (12) was predominant in the equilibrium, while 3-amino-5-phenyl-1,2,4-triazole (12’) 
was found to exist in minor proportion (KT = 8.2, ΔG298 = -5.2 kJ mol-1), whereas the 4H-form 12’’ 
was not detected.  
Benzotriazole has been shown to be a very effective auxiliary8 and we attempted to apply 1-
guanylbenzotriazole hydrochloride9 as a guanylating agent10 in the reaction with 12. It was found that 
the guanylbenzotriazole selectively attacked endocyclic nitrogen N-1 of the triazole 12 affording 6 as 
hydrochloride which was converted to the base using sodium carbonate. The target 7-amino-4,5-
dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines (3) were prepared in good yields via (5+1) 
heterocyclization of 6 using aldehydes or ketones 7 as one-carbon inserting reagents (Scheme 5, Table 
2).  
Both 5-amino-6,7-dihydro- and 7-amino-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines (2 and 3) 
might be involved in the annular tautomerism (Scheme 6). However, the indicated forms were found to 
be predominant. The coupling of proton at sp3-hybridized carbon and NH proton in 1H NMR spectra 
was observed for several compounds (J=0-1.5 Hz). Despite J value was small and not always 
detectable, 2D NOESY experiments clearly indicated that NH proton located in the vicinity of sp3-
hybridized carbon. The same tautomeric preferences were found in solid state as confirmed by X-ray 
crystallography of 2h and 3h (Fig. 2 and 3).1,6 Interestingly, two almost identical individual molecules 
with the intermediate between a twist boat and a half-boat conformation were identified for compound 
3h in the crystal (Fig. 3).  
 
3. Conclusion 
In summary, the synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazines with potential antifolate activity was 
successfully developed and their structures were investigated. The preparation method is practical: it 
required simple and easily available starting materials and provided derivatives of the interesting 5-
azapurine system in 3-4 steps starting from benzhydrazide.  
 
4. Experimental section 
 
4.1. General  
Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus. Analytical 
TLC were carried out on aluminum plates coated with Silica gel 60 F254 (Merck) with detection by UV 
light. Mass spectra were obtained on a Finnigan MAT LCQ LC-MS mass spectrometer using 
atmospheric pressure chemical ionization (APCI) mode. IR spectra were recorded in KBr pellets using 
a Shimadzu IRPrestige-21 FTIR spectrophotometer. 1H and 13C NMR spectra were recorded on a 
Bruker DPX-300 spectrometer using DMSO-d6 as a solvent and TMS as an internal reference. The 
energy of activation (ΔG‡) for the equilibrium between 11 and 11’ was estimated at the temperature of 
coalescence using dynamic 1H NMR experiments (0.1 M solution in DMSO-d6). The tautomeric 
preferences for 12 were investigated using 1H NMR spectral data (0.1 M solution in DMSO-d6 at 27 
°C).  
 
4.2. N-Benzamidobiguanide hydrochloride (8).11  
To the solution of benzhydrazide (1, 6.80 g, 50 mmol) in EtOH (35 ml), conc. HCl (5 ml, 50 mmol) 
and cyanoguanidine (4.62 g, 55 mmol) were added. The reaction mixture was heated under reflux with 
stirring for 4 h. After cooling on ice, the product was filtered, washed with cold EtOH and dried to give 
white powder. White crystalline powder; yield 80%, mp 172-173 °C (EtOH) [lit.11 mp 169-170 °C]. 1H 
NMR (300 MHz, DMSO-d6): δ 7.10 (br s, 4H, NH-C(=NH)NH2), 7.51 (t, 2H, 3J=7.3 Hz, H-3 and H-
5), 7.60 (t, 1H, 3J=7.2 Hz, H-4), 7.67 (br s, 2H, NH2), 7.97 (d, 2H, 3J=7.2 Hz, H-2 and H-6), 9.37 (br s, 
1H, NH), 10.74 (br s, 1H, CONH).  
 
4.3. N-(3-Phenyl-1H-1,2,4-triazol-5-yl)guanidine (9).12  
N-Benzamidobiguanide hydrochloride (8, 5.13 g, 20 mmol) was heated at 80 °C in 10% aqueous 
sodium hydroxide solution (10 ml) for 6 h. After cooling, the product was filtered, washed with cold 
water and dried. White crystalline powder; yield 68%, mp 242-243 °C [lit.12 mp 244-246 °C]. TLC 
(silica gel, EtOH): Rf 0.16. 1H NMR (300 MHz, DMSO-d6): δ 6.58 (br s, 4H, NH-C(=NH)NH2), 7.33 
(t, 1H, 3J=7.1 Hz, H-4’), 7.41 (t, 2H, 3J=7.1 Hz, H-3’ and H-5’), 7.96 (d, 2H, 3J=7.1 Hz, H-2’ and H-
6’), 12.40 (br s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 125.2 (2C), 128.0, 128.3 (2C), 139.2, 
157.0, 157.7, 160.5.  
 
4.4. N-Benzamidoguanidine (11).7  
The mixture of benzhydrazide (1, 13.6 g, 100 mmol) and S-methylisothiouronium sulfate (13.9 g, 50 
mmol) in 1% aqueous sodium hydroxide solution (400 ml) was stirred at rt for 72 h and then heated to 
50 °C for another 3 h. After cooling, the precipitated product was filtered, washed with ice-cold water 
and dried. White powder; yield 86%, mp 176 ºC [lit.7 mp 184 ºC]. 1H NMR (300 MHz, DMSO-d6): δ 
6.97 (br s, 2H, NH2), 7.16 (br s, 2H, NH2), 7.23-7.35 (m, 3H, W1/2=9 Hz, H-3, H-4 and H-5), 7.89-8.01 
(m, 2H, W1/2=12 Hz, H-2 and H-6), 11.01 (br s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 126.5 
(2C), 127.3 (2C), 128.0, 138.5, 152.9, 160.5.  
 
4.5. 3(5)-Phenyl-1,2,4-triazol-5(3)-amine (12).13  
N-Benzamidoguanidine (11, 8.90 g, 50 mmol) was heated under reflux in 80 ml of water for 4 h. After 
cooling, the precipitated amino-1,2,4-triazole 12 was filtered, washed with ice-cold water and dried. 
Colorless crystals; yield 97%, mp 186-187 ºC [lit.13 mp 186-187 ºC]. TLC (silica gel, EtOH): Rf 0.59. 
1H NMR (300 MHz, DMSO-d6): δ 5.29* and 6.05 (two br s, 2H, NH2), 7.32 (t, 1H, 3J=7.2 Hz, H-4’), 
7.39 (t, 2H, 3J=7.2 Hz, H-3’ and H-5’), 7.89 (d, 2H, 3J=6.8 Hz, H-2’ and H-6’), 12.04 and 13.20* (two 
br s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 125.2 (2C), 128.0, 128.2 (2C), 132.3, 157.2, 158.3.  
* - signals of the minor tautomeric form  
 
4.6. 1-Guanylbenzotriazole hydrochloride.14  
To the stirred mixture of benzotriazole (8.9 g, 75 mmol) and cyanamide (6.3 g, 150 mmol) at 100 °C, 
conc. HCl (8.5 ml, 85 mmol) was added. When vigorous reaction was completed, the mixture was 
heated for 15 min at 100 °C. Then, 1 M HCl (12 ml) was added. After cooling, the precipitated 1-
guanylbenzotriazole hydrochloride was filtered, washed with ice-cold 1 M HCl and dried. White 
powder; yield 68%, mp 194-196 °C [lit.14 mp 195-197 °C]. 1H NMR (300 MHz, DMSO-d6): δ 7.67 (t, 
1H, 3J=7.7 Hz, H-3), 7.87 (t, 1H, 3J=7.7 Hz, H-5), 8.08 (d, 1H, 3J=8.3 Hz, H-4), 8.32 (d, 1H, 3J=8.3 
Hz, H-7), 10.23 (s, 4H, C(=NH)NH2∙HCl). 13C NMR (75 MHz, DMSO-d6): δ 112.8, 120.2, 126.5, 
130.4, 130.5, 145.6, 152.1.  
 
4.7. 1-Guanyl-3-phenyl-1,2,4-triazol-5-amine hydrochloride (6∙HCl).9b  
To the solution of 3(5)-phenyl-1,2,4-triazol-5(3)-amine (12, 6.80 g, 40 mmol) in EtOH (35 ml), 1-
guanylbenzotriazole hydrochloride (7.88 g, 40 mmol) was added. The reaction mixture was heated 
under reflux with stirring for 30 min. After cooling, the product was filtered, washed with cold EtOH 
and dried. White crystalline powder; yield 62%, mp 212 °C [lit.9b mp 210 °C]. 1H NMR (300 MHz, 
DMSO-d6): δ 7.46-7.56 (m, 3H, H-3’, H-4’ and H-5’), 7.71 (s, 2H, NH2), 8.00 (dd, 2H, 3J=6.4, 4J=3.0 
Hz, H-2’ and H-6’), 9.47 (s, 4H, C(=NH)NH2∙HCl). 13C NMR (75 MHz, DMSO-d6): δ 126.4 (2C), 
128.7 (2C), 129.4, 130.3, 151.9, 157.0, 160.8.  
 
4.8. 1-Guanyl-3-phenyl-1,2,4-triazol-5-amine (6).9b 
The sodium carbonate solution (10%, 30 ml) was added to the solution of 1-guanyl-3-phenyl-1,2,4-
triazol-5-amine hydrochloride (6∙HCl, 5.95 g, 25 mmol) in water (15 ml). After cooling, the product 
was filtered, washed with cold water and dried. White powder; yield 92%, mp 168 °C [lit.9b mp 165 
°C]. TLC (silica gel, EtOH): Rf 0.59. 1H NMR (300 MHz, DMSO-d6): δ 6.36 (s, 1H, NH), 6.54 (s, 2H, 
NH2), 7.37-7.53 (m, 3H, H-3’, H-4’ and H-5’), 7.88 (s, 2H, NH2), 7.98 (dd, 2H, 3J=7.3, 4J=1.7 Hz, H-
2’ and H-6’). 13C NMR (75 MHz, DMSO-d6): δ 125.9 (2C), 128.4 (2C), 129.2, 130.7, 152.7, 156.6, 
156.8.  
 
4.9. General method for preparation of 7-(het)aryl-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-amines (2a-g).  
The solution of N-(3-phenyl-1H-1,2,4-triazol-5-yl)guanidine (5, 0.50 g, 2.5 mmol), appropriate 
aldehyde (7a-g, 2.5 mmol) and piperidine (0.10 ml, 1.0 mmol) in EtOH (7-10 ml) was heated under 
reflux for 3-18 h. After cooling, the product was filtered, washed with cold EtOH, dried and 
recrystallized from EtOH, DMF or their mixture.  
 
4.9.1. 2,7-Diphenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2a). White crystalline 
powder; yield 92%; mp 300-301 °C. TLC (silica gel, EtOH): Rf 0.57. LC-MS (APCI) m/z 291 (MH+). 
Anal. Calcd for C16H14N6: C 66.19; H 4.86; N 28.95. Found: C 66.02; H 4.95; N 28.73%. IR (KBr): ν 
3461, 3311, 3237, 3135, 1653, 1646, 1597, 1548, 1522 (m), 1474, 1460, 1444, 1434, 1411, 1371, 764, 
747, 713, 691 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 6.42 (s, 2H, NH2), 6.69 (s, 1H, H-7), 7.29-7.47 
(m, 8H, H-3’, H-4’, H-5’ and 5-Ph), 7.86 (dd, 2H, 3J=7.9, 4J=1.5 Hz, H-2’ and H-6’), 7.93 (d, 1H, 
3J=1.5 Hz, NH). 13C NMR (75 MHz, DMSO-d6): δ 68.3, 125.3 (2C), 126.2 (2C), 128.3 (2C), 128.4, 
128.7 (2C), 129.0, 131.7, 140.4, 155.5, 156.4, 159.2.  
 
4.9.2. 7-(4-Methoxylphenyl)-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2b). 
White crystalline powder; yield 91%, mp 291 °C. TLC (silica gel, EtOH): Rf 0.54. LC-MS (APCI) m/z 
321 (MH+). Anal. Calcd for C17H16N6O: C 63.74; H 5.03; N 4.99. Found: C 63.70; H 5.12; N 4.91%. 
IR (KBr): ν 3451, 3309, 3227, 3110, 1653, 1647, 1594, 1523 (m), 1477, 1435, 1409, 1369, 1254, 1178, 
815, 746, 688 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 3.75 (s, 3H, OMe), 6.39 (s, 2H, NH2), 6.63 (d, 
1H, 3J=0.8 Hz, H-7), 6.97 (d, 2H, 3J=8.7 Hz, H-3’’ and H-5’’), 7.28 (d, 2H, 3J=8.7 Hz, H-2’’ and H-
6’’), 7.35 (t, 2H, 3J=7.5 Hz, H-3’ and H-5’), 7.37 (t, 1H, 3J=7.5 Hz, H-4’), 7.86 (d, 2H, 3J=7.5 Hz, H-
2’ and H-6’), 7.87 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 55.1, 68.0, 114.0 (2C), 125.3 (2C), 
127.6 (2C), 128.3 (2C), 128.4, 131.8, 132.5, 155.5, 156.3, 159.1, 159.7.  
 
4.9.3. 7-(4-Methylphenyl)-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2c). 
White crystalline powder; yield 90%, mp 281 °C. TLC (silica gel, EtOH): Rf 0.57. LC-MS (APCI) m/z 
305 (MH+). Anal. Calcd for C17H16N6: C 67.09; H 5.30; N 27.61. Found: C 66.92; H 5.34; N 27.55%. 
IR (KBr): ν 3462, 3311, 3231, 3111, 1652, 1648, 1599, 1522 (m), 1477, 1444, 1435, 1409, 1365, 805, 
745, 689 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 2.29 (s, 3H, Me), 6.40 (s, 2H, NH2), 6.65 (d, 1H, 
3J=1.5 Hz, H-7), 7.20-7.25 (m, 4H, H-2’’, H-3’’, H-5’’ and H-6’’), 7.32-7.41 (m, 3H, H-3’, H-4’ and 
H-5’), 7.86 (dd, 2H, 3J=8.1, 4J=1.7 Hz, H-2’ and H-6’), 7.89 (d, 1H, 3J=1.5 Hz, NH). 13C NMR (75 
MHz, DMSO-d6): δ 20.7, 68.2, 125.3 (2C), 126.2 (2C), 128.3 (2C), 128.4, 129.2 (2C), 131.8, 137.6, 
138.5, 155.5, 156.3, 159.1.  
 
4.9.4. 7-(4-Chlorophenyl)-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2d). 
White crystalline powder; yield 73%, mp 290 °C. TLC (silica gel, EtOH): Rf 0.56. LC-MS (APCI) m/z 
325, 327 (MH+). Anal. Calcd for C16H13ClN6: C 59.17; H 4.03; N 25.88. Found: C 59.02; H 4.19; N 
25.73%. IR (KBr): ν 3446, 3309, 3237, 3111, 1653, 1647, 1595, 1525 (m), 1472, 1433, 1396, 1363, 
745, 689 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 6.48 (s, 2H, NH2), 6.74 (s, 1H, H-7), 7.29-7.44 (m, 
5H, H-2’’, H-6’’, H-3’, H-4’ and H-5’), 7.51 (d, 2H, 3J=8.3 Hz, H-3’’ and H-5’’), 7.87 (d, 2H, 3J=7.5 
Hz, H-2’ and H-6’), 7.97 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 67.6, 125.4 (2C), 128.2 (2C), 
128.3 (2C), 128.5, 128.8 (2C), 131.7, 133.6, 139.3, 155.4, 156.4, 159.4.  
 
4.9.5. 7-(4-Fluorophenyl)-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2e). 
White crystalline powder; yield 76%, mp 280-281 °C. TLC (silica gel, EtOH): Rf 0.56. LC-MS (APCI) 
m/z 309 (MH+). Anal. Calcd for C16H13FN6: C 62.33; H 4.25; N 27.26. Found: C 62.21; H 4.34; N 
27.19%. IR (KBr): ν 3469, 3310, 3236, 3112, 1653, 1647, 1601, 1524 (m), 1476, 1436, 1409, 1363, 
1239, 821, 746, 688 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 6.45 (s, 2H, NH2), 6.73 (s, 1H, H-7), 7.27 
(dd, 2H, 3JHF=8.9, 3J=8.9 Hz, H-3’’ and H-5’’), 7.32-7.47 (m, 5H, H-3’, H-4’, H-5’, H-2’’ and H-6’’), 
7.86 (d, 2H, 3J=7.5 Hz, H-2’ and H-6’), 7.94 (d, 1H, 3J = 1.5 Hz, NH). 13C NMR (75 MHz, DMSO-d6): 
δ 67.6, 115.6 (d, 2JCF=21.8 Hz, 2C), 125.4 (2C), 128.3 (2C), 128.5, 127.5 (d, 3JCF=8.8 Hz, 2C), 131.7, 
136.7 (d, 4JCF=2.9 Hz), 155.5, 156.4, 159.4, 162.3 (d, 1JCF=245.2 Hz).  
 
4.9.6. 7-(2-Furyl)-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2f).  Beige 
crystalline powder; yield 72%, mp 272 °C. TLC (silica gel, EtOH): Rf 0.56. LC-MS (APCI) m/z 281 
(MH+). Anal. Calcd for C14H12N6O: C 59.99; H 4.32; N 29.98. Found: C 59.78; H 4.43; N 29.89%. IR 
(KBr): ν 3472, 3448, 3313, 3232, 3105, 1655, 1651, 1603, 1523 (m), 1477, 1436, 1395, 1364, 830, 
750, 693 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 6.45 (s, 2H, NH2), 6.47 (dd, 1H, 3J=3.1, 3J=1.7 Hz, 
H-4’’), 6.54 (d, 1H, 3J=3.1 Hz, H-3’’), 6.81 (s, 1H, H-7), 7.30-7.45 (m, 3H, H-3’, H-4’ and H-5’), 7.68 
(d, 1H, 3J=1.7 Hz, H-5’’), 7.88 (dd, 2H, 3J=7.5, 4J=1.5 Hz, H-2’ and H-6’), 7.92 (s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 62.2, 108.7, 110.5, 125.4 (2C), 128.3 (2C), 128.5, 131.7, 143.8, 151.5, 
155.5, 156.3, 159.3.  
 
4.9.7. 2-Phenyl-7-(4-pyridyl)-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2g). 
Yellowish crystalline powder; yield 78%, mp 242-244 °C. TLC (silica gel, EtOH): Rf 0.30. LC-MS 
(APCI) m/z 292 (MH+). Anal. Calcd for C15H13N7: C 61.84; H 4.50; N 33.66. Found: C 61.63; H 4.62; 
N 33.50%. IR (KBr): ν 3447, 3324, 3107, 3079, 1653, 1647, 1624, 1606, 1521 (m), 1437, 1420, 1362, 
1295, 741, 685 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 6.56 (s, 2H, NH2), 6.77 (s, 1H, H-7), 7.23-7.48 
(m, 5H, H-2’’, H-6’’, H-3’, H-4’ and H-5’), 7.89 (d, 2H, 3J=7.5 Hz, H-2’ and H-6’), 8.06 (s, 1H, NH), 
8.64 (d, 2H, 3J=5.3 Hz, H-3’’ and H-5’’). 13C NMR (75 MHz, DMSO-d6): δ 67.0, 120.9 (2C), 125.4 
(2C), 128.3 (2C), 128.6, 131.6, 148.2, 150.2 (2C), 155.5, 156.4, 159.6.  
 
4.10. 7,7-Dimethyl-2-phenyl-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amine (2h). The 
mixture of N-(3-phenyl-1H-1,2,4-triazol-5-yl)guanidine (5, 0.50 g, 2.5 mmol) and piperidine (0.10 ml, 
1.0 mmol) in acetone (7 ml) was heated under reflux for 18 h. After cooling, the precipitated product 
was filtered, washed with acetone, dried and recrystallized from EtOH. White crystalline powder; yield 
98%, mp 294 °C. TLC (silica gel, EtOH): Rf 0.50. LC-MS (APCI) m/z 243 (MH+). Anal. Calcd for 
C12H14N6: C 59.49; H 5.82; N 34.69. Found: C 59.45; H 5.86; N 34.64%. IR (KBr): ν 3473, 3308, 
3230, 3055, 2977, 1654, 1651, 1616, 1559, 1528 (m), 1476, 1460, 1444, 1420, 1362, 1172, 748, 699, 
691, 476 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 1.64 (s, 6H, Me2), 6.21 (s, 2H, NH2), 7.36-7.40 (m, 
3H, H-3’, H-4’ and H-5’), 7.58 (s, 1H, NH), 7.92 (dd, 2H, 3J=8.3, 4J=1.5 Hz, H-2’ and H-6’). 13C 
NMR (75 MHz, DMSO-d6): δ 28.7 (2C), 70.1, 125.3 (2C), 128.3 (3C), 132.1, 155.5, 155.8, 158.7.  
 
4.11. General method for preparation of the spiro derivatives of 2-phenyl-6,7-
dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-amines (2i,j). The solution of N-(3-phenyl-1H-1,2,4-
triazol-5-yl)guanidine (9, 0.50 g, 2.5 mmol), appropriate cyclic ketone (7i,j, 5.0 mmol) and piperidine 
(0.10 ml, 1.0 mmol) in EtOH (8 ml) was heated under reflux for 16-24 h. After cooling, the product 
was filtered, washed with cold EtOH, dried and recrystallized from EtOH/DMF.  
 
4.11.1. 2'-Phenyl-6'H-spiro[cyclopentane-1,7'-[1,2,4]triazolo[1,5-a][1,3,5]triazin]-5'-amine (2i). 
White crystalline powder; yield 96%, mp 300 °C. TLC (silica gel, EtOH): Rf 0.54. LC-MS (APCI) m/z 
269 (MH+). Anal. Calcd for C14H16N6: C 62.67; H 6.01; N 31.32. Found: C 62.46; H 6.17; N 31.19%. 
IR (KBr): ν 3471, 3280, 3204, 3123, 2962, 1653, 1635, 1630, 1598, 1523 (m), 1473, 1435, 1419, 1362, 
753, 703 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 1.71-1.97 (m, 6H, (CH2)2, H-2a and H-5a), 2.21-
2.37 (m, 2H, H-2e and H-5e), 6.20 (s, 2H, NH2), 7.34 (t, 1H, 3J=7.0 Hz, H-4’), 7.46 (t, 2H, 3J=7.2 Hz, 
H-3’ and H-5’), 7.73 (s, 1H, NH), 7.92 (d, 2H, 3J=7.2 Hz, H-2’ and H-6’). 13C NMR (75 MHz, DMSO-
d6): δ 23.0 (2C), 39.6 (2C), 79.6, 125.3 (2C), 128.3 (3C), 132.0, 155.5, 156.2, 158.7.  
 
4.11.2. 2'-Phenyl-6'H-spiro[cyclohexane-1,7'-[1,2,4]triazolo[1,5-a][1,3,5]triazin]-5'-amine (2j). 
White crystalline powder; yield 72%, mp 283 °C. TLC (silica gel, EtOH): Rf 0.58. LC-MS (APCI) m/z 
283 (MH+). Anal. Calcd for C15H18N6: C 63.81; H 6.43; N 29.77. Found: C 63.72; H 6.65; N 29.58%. 
IR (KBr): ν 3463, 3363, 3309, 3134, 2933, 1653, 1647, 1636, 1587, 1558, 1534, 1521 (m), 1473, 1444, 
1409, 1356, 753, 710, 693 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 1.22-1.71 (m, 8H, (CH2)3, H-2a 
and H-6a), 2.00-2.18 (m, 2H, H-2e and H-6e), 6.28 (s, 2H, NH2), 7.30-7.45 (m, 3H, H-3’, H-4’ and H-
5’), 7.45 (s, 1H, NH), 7.92 (dd, 2H, 3J=8.0, 4J=1.5 Hz, H-2’ and H-6’). 13C NMR (75 MHz, DMSO-
d6): δ 20.8 (2C), 24.0, 36.4 (2C), 71.2, 125.3 (2C), 128.3 (3C), 132.1, 155.5, 155.8, 158.5.  
 
4.12. General method for preparation of 5-(het)aryl-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-amines (3a-g).  
The solution of 1-guanyl-3-phenyl-1,2,4-triazol-5-amine (6, 0.50 g, 2.5 mmol), appropriate aldehyde 
(7a-g, 2.5 mmol) and piperidine (0.10 ml, 1.0 mmol) in EtOH (7-10 ml) was heated under reflux for 2-
12 h. After cooling, the product was filtered, washed with cold EtOH, dried and recrystallized from 
EtOH, DMF or their mixture.  
 
4.12.1. 2,5-Diphenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3a). White crystalline 
powder; yield 78%, mp 204-205 °C. TLC (silica gel, EtOH): Rf 0.62. LC-MS (APCI) m/z 291 (MH+). 
Anal. Calcd for C16H14N6: C 66.19; H 4.86; N 28.95. Found: C 66.05; H 5.07; N 28.73%. IR (KBr): ν 
3437, 3231, 3133, 1706, 1697, 1626, 1531, 1495, 1450, 1434, 1340, 1026, 730, 701, 685 cm-1. 1H 
NMR (300 MHz, DMSO-d6): δ 5.91 (s, 1H, H-5), 6.60 (s, 2H, NH2), 7.25-7.53 (m, 8H, H-3’, H-4’, H-
5’ and 5-Ph), 8.00 (dd, 2H, 3J=7.3, 4J=2.4 Hz, H-2’ and H-6’), 8.68 (s, 1H, NH). 13C NMR (75 MHz, 
DMSO-d6): δ 68.2, 126.2 (2C), 126.3 (2C), 127.7, 128.1 (2C), 128.5 (2C), 129.6, 130.5, 142.9, 143.4, 
156.1, 159.8.  
 
4.12.2. 5-(4-Methoxyphenyl)-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 
(3b). White crystalline powder; yield 87%, mp 212 °C. TLC (silica gel, EtOH): Rf 0.55. LC-MS 
(APCI) m/z 321 (MH+). Anal. Calcd for C17H16N6O: C 63.74; H 5.03; N 4.99. Found: C 63.60; H 5.23; 
N 4.81%. IR (KBr): ν 3439, 3231, 3126, 1706, 1697, 1624, 1534, 1511, 1499, 1451, 1437, 1343, 1252, 
1036, 737, 690 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 3.74 (s, 3H, OMe), 5.84 (s, 1H, H-5), 6.54 (s, 
2H, NH2), 6.92 (d, 2H, 3J=8.7 Hz, H-3’’ and H-5’’), 7.37 (d, 2H, 3J=8.7 Hz, H-2’’ and H-6’’), 7.42-
7.52 (m, 3H, H-3’, H-4’ and H-5’), 7.98 (dd, 2H, 3J=7.2, 4J=2.3 Hz, H-2’ and H-6’), 8.58 (s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ 55.0, 67.8, 113.4 (2C), 126.2 (2C), 127.5 (2C), 128.5 (2C), 129.6, 
130.5, 135.0, 143.4, 156.1, 158.7, 159.8.  
 
4.12.3. 5-(4-Methylphenyl)-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3c). 
White crystalline powder; yield 72%, mp 213-214 °C. TLC (silica gel, EtOH): Rf 0.58. LC-MS (APCI) 
m/z 305 (MH+). Anal. Calcd for C17H16N6: C 67.09; H 5.30; N 27.61. Found: C 66.86; H 5.52; N 
27.53%. IR (KBr): ν 3440, 3224, 3125, 1702, 1696, 1624, 1532, 1496, 1452, 1437, 1343, 1034, 758, 
735, 686 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 2.29 (s, 3H, Me), 5.86 (s, 1H, H-5), 6.56 (s, 2H, 
NH2), 7.17 (d, 2H, 3J=7.9 Hz, H-3’’ and H-5’’), 7.32 (d, 2H, 3J=7.9 Hz, H-2’’ and H-4’’), 7.41-7.51 
(m, 3H, H-3’, H-4’ and H-5’), 7.98 (dd, 2H, 3J=7.2, 4J=2.2 Hz, H-2’ and H-6’), 8.61 (s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 20.6, 68.0, 126.1 (2C), 126.2 (2C), 128.5 (2C), 128.6 (2C), 129.6, 130.5, 
136.8, 140.0, 143.4, 156.1, 159.8.  
 
4.12.4. 5-(4-Chlorophenyl)-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3d). 
White crystalline powder; yield 70%, mp 220-221 °C. TLC (silica gel, EtOH): Rf 0.60. LC-MS (APCI) 
m/z 325, 327 (MH+). Anal. Calcd for C16H13ClN6: C 59.17; H 4.03; N 25.88. Found: C 58.94; H 4.32; 
N 25.62%. IR (KBr): ν 3444, 3228, 3124, 1705, 1697, 1628, 1533, 1498, 1490, 1454, 1437, 1343, 
1018, 773, 737, 689 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 5.92 (s, 1H, H-5), 6.62 (s, 2H, NH2), 
7.39-7.54 (m, 7H, H-3’, H-4’, H-5’, H-2’’, H-3’’, H-5’’ and H-6’’), 7.99 (dd, 2H, 3J=7.2, 4J=1.9 Hz, 
H-2’ and H-6’), 8.67 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 67.6, 126.2 (2C), 128.1 (2C), 
128.2 (2C), 128.5 (2C), 129.6, 130.4, 132.2, 141.9, 143.6, 156.0, 159.9.  
 
4.12.5. 5-(4-Fluorophenyl)-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3e). 
White crystalline powder; yield 78%, mp > 360 °C. TLC (silica gel, EtOH): Rf 0.63. LC-MS (APCI) 
m/z 309 (MH+). Anal. Calcd for C16H13FN6: C 62.33; H 4.25; N 27.26. Found: C 62.02; H 4.47; N 
27.11%. IR (KBr): ν 3441, 3225, 3134, 1706, 1697, 1627, 1601, 1532, 1507, 1496, 1449, 1436, 1340, 
1227, 1034, 771, 736, 687 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 5.93 (s, 1H, H-5), 6.63 (s, 2H, 
NH2), 7.20 (dd, 2H, 3JHF=8.9, 3J=8.9 Hz, H-3’’ and H-5’’) 7.43-7.54 (m, 5H, H-3’, H-4’, H-5’, H-2’’ 
and H-6’’), 8.00 (dd, 2H, 3J=7.3, 4J=2.4 Hz, H-2’ and H-6’), 8.68 (s, 1H, NH). 13C NMR (75 MHz, 
DMSO-d6): δ 67.6, 114.9 (d, 2JCF=21.8 Hz, 2C), 126.2 (2C), 128.4 (d, 3JCF=8.2 Hz, 2C), 128.5 (2C), 
129.6, 130.5, 139.1 (d, 4JCF=2.9 Hz), 143.6, 156.1, 159.9, 161.6 (d, 1JCF=243.4 Hz).  
 
4.12.6. 5-Furyl-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3f).  Beige 
crystalline powder; yield 70%, mp 210 °C. TLC (silica gel, EtOH): Rf 0.62. LC-MS (APCI) m/z 281 
(MH+). Anal. Calcd for C14H12N6O: C 59.99; H 4.32; N 29.98. Found: C 59.83; H 4.46; N 29.84%. IR 
(KBr): ν 3305, 3240, 3159, 1702, 1698, 1637, 1529, 1457, 1438, 1342, 1233, 1015, 755 cm-1. 1H NMR 
(300 MHz, DMSO-d6): δ 5.94 (d, 1H, 3J=1.1 Hz, H-5), 6.29 (d, 1H, 3J=3.0 Hz, H-5’’), 6.40 (dd, 1H, 
3J=3.0, 3J=1.8 Hz, H-4’’), 6.63 (s, 2H, NH2), 7.41-7.52 (m, 3H, H-3’, H-4’ and H-5’), 7.59 (d, 1H, 
3J=1.8 Hz, H-3’’), 7.99 (dd, 2H, 3J=7.3, 4J=2.4 Hz, H-2’ and H-6’), 8.74 (d, 1H, 3J=1.1 Hz, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 62.3, 105.8, 110.1, 126.1 (2C), 128.5 (2C), 129.6, 130.4, 142.4, 144.2, 
154.9, 155.5, 159.6.  
 
4.12.7. 2-Phenyl-5-(4-pyridyl)-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3g). 
Yellowish crystalline powder; yield 68%, mp 333-335 °C. TLC (silica gel, EtOH): Rf 0.38. LC-MS 
(APCI) m/z 292 (MH+). Anal. Calcd for C15H13N7: C 61.84; H 4.50; N 33.66. Found: C 61.63; H 4.76; 
N 33.52%. IR (KBr): ν 3442, 3230, 3126, 1705, 1697, 1625, 1533, 1496, 1453, 1436, 1416, 1340, 
1036, 771, 735, 685 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 5.96 (s, 1H, H-5), 6.72 (s, 2H, NH2), 
7.39-7.54 (m, 5H, H-3’, H-4’, H-5’, H-2’’ and H-6’’), 8.00 (dd, 2H, 3J=7.0, 4J=2.4 Hz, H-2’ and H-6’), 
8.59 (dd, 2H, 3J=4.7, 4J=1.3 Hz, H-3’’ and H-5’’), 8.81 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 
67.1, 121.3 (2C), 126.2 (2C), 128.5 (2C), 129.7, 130.4, 143.8, 149.7 (2C), 151.1, 155.9, 159.9.  
 
4.13. 5,5-Dimethyl-2-phenyl-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (3h). The 
mixture of 1-guanyl-3-phenyl-1,2,4-triazol-5-amine (6, 0.50 g, 2.5 mmol) and piperidine (0.10 ml, 1.0 
mmol) in acetone (7 ml) was heated under reflux for 12 h. After cooling, the precipitated product was 
filtered, washed with acetone, dried and recrystallized from EtOH. White crystalline powder; yield 
65%, mp 210 °C. TLC (silica gel, EtOH): Rf 0.55. LC-MS (APCI) m/z 243 (MH+). Anal. Calcd for 
C12H14N6: C 59.49; H 5.82; N 34.69. Found: C 59.31; H 6.03; N 34.56%. IR (KBr): ν 3414, 3388, 
3072, 2965, 1705, 1698, 1624, 1522, 1495, 1448, 1431, 1380 (d, gem-Me2), 1340, 913, 740, 705, 694 
cm-1. 1H NMR (300 MHz, DMSO-d6): δ 1.37 (s, 6H, Me2), 6.30 (s, 2H, NH2), 7.42-7.51 (m, 3H, H-3’, 
H-4’ and H-5’), 7.98 (dd, 2H, 3J=7.2, 4J=1.9 Hz, H-2’ and H-6’), 8.25 (s, 1H, NH). 13C NMR (75 
MHz, DMSO-d6): δ 30.5 (2C), 68.8, 126.1 (2C), 128.5 (2C), 129.5, 130.7, 141.5, 155.4, 159.5.  
 
4.14. General method for preparation of the spiro derivatives of 2-phenyl-4,5-
dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amines (3i,j).  
The solution of 1-guanyl-3-phenyl-1,2,4-triazol-5-amine (6, 0.50 g, 2.5 mmol), appropriate cyclic 
ketone (7i,j, 5.0 mmol) and piperidine (0.10 ml, 1.0 mmol) in EtOH (8 ml) was heated under reflux for 
10-15 h. After cooling, the product was filtered, washed with cold EtOH, dried and recrystallized from 
EtOH.  
 
4.14.1. 2'-Phenyl-4'H-spiro[cyclopentane-1,5'-[1,2,4]triazolo[1,5-a][1,3,5]triazin]-7'-amine (3i). 
White crystalline powder; yield 62%, mp 206-207 °C. TLC (silica gel, EtOH): Rf 0.60. LC-MS (APCI) 
m/z 269 (MH+). Anal. Calcd for C14H16N6: C 62.67; H 6.01; N 31.32. Found: C 62.50; H 6.22; N 
31.16%. IR (KBr): ν 3389, 3246, 3074, 2959, 1702, 1698, 1628, 1527, 1494, 1452, 1436, 1374, 1344, 
743, 690 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 1.62-1.87 (m, 8H, (CH2)4), 6.30 (s, 2H, NH2), 7.39-
7.52 (m, 3H, H-3’, H-4’ and H-5’), 7.98 (dd, 2H, 3J=7.5, 4J=1.9 Hz, H-2’ and H-6’), 8.33 (s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ 22.2 (2C), 41.0 (2C), 78.9, 126.1 (2C), 128.5 (2C), 129.5, 130.7, 
141.7, 155.9, 159.6.  
 
4.14.2. 2'-Phenyl-4'H-spiro[cyclohexane-1,5'-[1,2,4]triazolo[1,5-a][1,3,5]triazin]-7'-amine (3j). 
White crystalline powder; yield 73%, mp 216-217 °C. TLC (silica gel, EtOH): Rf 0.59. LC-MS (APCI) 
m/z 283 (MH+). Anal. Calcd for C15H18N6: C 63.81; H 6.43; N 29.77. Found: C 63.57; H 6.53; N 
29.64%. IR (KBr): ν 3374, 3287, 3072, 2936, 2922, 1702, 1698, 1635, 1527, 1491, 1451, 1430, 1354, 
746, 692 cm-1. 1H NMR (300 MHz, DMSO-d6): δ 1.25-1.81 (m, 10H, (CH2)5), 6.31 (s, 2H, NH2), 7.39-
7.54 (m, 3H, H-3’, H-4’ and H-5’), 7.99 (dd, 2H, 3J=7.3, 4J=1.7 Hz, H-2’ and H-6’), 8.20 (s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6): δ 21.3 (2C), 25.0, 38.9 (2C), 70.3, 126.1 (2C), 128.5 (2C), 129.5, 
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Table 1. 5-Amino-6,7-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines (2)  
2 R1 R2 Yields (%) 
a H Ph 92 
b H 4-MeO-C6H4 91 
c H 4-Me-C6H4 90 
d H 4-Cl-C6H4 73 
e H 4-F-C6H4 76 
f H 2-Furyl 72 
g H 4-Py 78 
h Me Me 98 
i -(CH2)4- 96 




Table 2. 7-Amino-4,5-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines (3)  
3 R1 R2 Yield (%) 
a H Ph 78 
b H 4-MeO-C6H4 87 
c H 4-Me-C6H4 72 
d H 4-Cl-C6H4 70  
e H 4-F-C6H4 78 
f H 2-Furyl 70 
g H 4-Py 68 
h Me Me 65 
i -(CH2)4- 62 
j -(CH2)5- 73 
 
 
Figure and Scheme Legends  
 
Figure 1. Selected antifolate 1,3,5-triazines and the compounds of interest  
 
Figure 2. X-ray crystal structure of 2h  
 
Figure 3. X-ray crystal structure of 3h  
 
Scheme 1. Design of the 5(7)-amino-6,7(4,5)-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines synthesis  
 
Scheme 2. Reagents and conditions: (i) cyanoguanidine (1.1 equiv), HCl (1 equiv), EtOH, 4 h, reflux 
(80%); (ii) 10% NaOH, 6 h, 80 °C (68%)  
 
Scheme 3. Reagents and conditions: (i) 7a-g (1 equiv) or 7i,j (2 equiv), EtOH, piperidine (0.4 equiv), 
3-24 h, reflux (72-96%); for 2h acetone, piperidine (0.4 equiv), 18 h, reflux (98%)  
 
Scheme 4. Reagents and conditions: (i) S-methylisothiouronium sulfate (0.5 equiv), NaOH (1 equiv), 
H2O, 72 h, rt, 3 h, 50 °C (86%); (ii) H2O, 4 h, reflux (97%)  
 
Scheme 5. Reagents and conditions: (i) guanylbenzotriazole hydrochloride (1 equiv), EtOH, 30 min, 
reflux 62%; (ii) 10% Na2CO3, 25 °C (92%); (iii) 7a-g (1 equiv) or 7i,j (2 equiv), EtOH, piperidine (0.4 
equiv), 2-15 h, reflux (62-87%); for 3h acetone, piperidine (0.4 equiv), 12 h, reflux (65%)  
 
















































Figure 1. Selected antifolate 1,3,5-triazines and the compounds of interest  
 
 
Figure 2. X-ray crystal structure of 2h  
 
 





























































Scheme 2. Reagents and conditions: (i) cyanoguanidine (1.1 equiv), HCl (1 equiv), EtOH, 4 h, reflux 


































Scheme 3. Reagents and conditions: (i) 7a-g (1 equiv) or 7i,j (2 equiv), EtOH, piperidine (0.4 equiv), 




































Scheme 4. Reagents and conditions: (i) S-methylisothiouronium sulfate (0.5 equiv), NaOH (1 equiv), 




























Scheme 5. Reagents and conditions: (i) guanylbenzotriazole hydrochloride (1 equiv), EtOH, 30 min, 
reflux (62%); (ii) 10% Na2CO3, 25 °C (92%); (iii) 7a-g (1 equiv) or 7i,j (2 equiv), EtOH, piperidine 





































































R1 = H, 3J = 0-1.5 Hz
NOE3
 
Scheme 6. Tautomerism in 5(7)-amino-6,7(4,5)-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazines  
 
 
